These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. No association of the hypercoagulable state with sickle cell disease related pulmonary hypertension. van Beers EJ; Spronk HM; Ten Cate H; Duits AJ; Brandjes DP; van Esser JW; Biemond BJ; Schnog JB; Haematologica; 2008 May; 93(5):e42-4. PubMed ID: 18450728 [No Abstract] [Full Text] [Related]
6. Rationale for IL-1beta targeted therapy for ischemia-reperfusion induced pulmonary and other complications in sickle cell disease. Wanderer AA J Pediatr Hematol Oncol; 2009 Aug; 31(8):537-8. PubMed ID: 19636265 [No Abstract] [Full Text] [Related]
7. Identification of oxidative post-translational modification of serum albumin in patients with idiopathic pulmonary arterial hypertension and pulmonary hypertension of sickle cell anemia. Odhiambo A; Perlman DH; Huang H; Costello CE; Farber HW; Steinberg MH; McComb ME; Klings ES Rapid Commun Mass Spectrom; 2007; 21(14):2195-203. PubMed ID: 17569101 [TBL] [Abstract][Full Text] [Related]
8. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Morris CR; Morris SM; Hagar W; Van Warmerdam J; Claster S; Kepka-Lenhart D; Machado L; Kuypers FA; Vichinsky EP Am J Respir Crit Care Med; 2003 Jul; 168(1):63-9. PubMed ID: 12626350 [TBL] [Abstract][Full Text] [Related]
9. Lactate dehydrogenase and hemolysis in sickle cell disease. Ballas SK Blood; 2013 Jan; 121(1):243-4. PubMed ID: 23287628 [No Abstract] [Full Text] [Related]
10. Association of soluble fms-like tyrosine kinase-1 with pulmonary hypertension and haemolysis in sickle cell disease. Ataga KI; Brittain JE; Jones SK; May R; Delaney J; Strayhorn D; Desai P; Redding-Lallinger R; Key NS; Orringer EP Br J Haematol; 2011 Feb; 152(4):485-91. PubMed ID: 21223248 [TBL] [Abstract][Full Text] [Related]
11. Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease. Schnog JB; Teerlink T; van der Dijs FP; Duits AJ; Muskiet FA; Ann Hematol; 2005 May; 84(5):282-6. PubMed ID: 15599544 [TBL] [Abstract][Full Text] [Related]
12. Massive quantities of asymmetric dimethylarginine (ADMA) are incorporated in red blood cell proteins and may be released by proteolysis following hemolytic stress. D'Alecy LG; Billecke SS Blood Cells Mol Dis; 2010 Jun; 45(1):40. PubMed ID: 20381387 [No Abstract] [Full Text] [Related]
13. Hemolytic anemia-associated pulmonary hypertension of sickle cell disease and the nitric oxide/arginine pathway. Jison ML; Gladwin MT Am J Respir Crit Care Med; 2003 Jul; 168(1):3-4. PubMed ID: 12826592 [No Abstract] [Full Text] [Related]
14. Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension. Skoro-Sajer N; Mittermayer F; Panzenboeck A; Bonderman D; Sadushi R; Hitsch R; Jakowitsch J; Klepetko W; Kneussl MP; Wolzt M; Lang IM Am J Respir Crit Care Med; 2007 Dec; 176(11):1154-60. PubMed ID: 17872491 [TBL] [Abstract][Full Text] [Related]
15. Plasma concentrations of asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell patients but do not increase further during painful crisis. Landburg PP; Teerlink T; Muskiet FA; Duits AJ; Schnog JJ; Am J Hematol; 2008 Jul; 83(7):577-9. PubMed ID: 18383318 [TBL] [Abstract][Full Text] [Related]
16. N-terminal natriuretic peptide and ventilation-perfusion lung scan in sickle cell disease and thalassemia patients with pulmonary hypertension. Mokhtar GM; Adly AA; El Alfy MS; Tawfik LM; Khairy AT Hemoglobin; 2010; 34(1):78-94. PubMed ID: 20113292 [TBL] [Abstract][Full Text] [Related]
17. Soluble CD163 in young sickle cell disease patients and their trait siblings: a biomarker for pulmonary hypertension and vaso-occlusive complications. Tantawy AA; Adly AA; Ismail EA Blood Coagul Fibrinolysis; 2012 Oct; 23(7):640-8. PubMed ID: 22885767 [TBL] [Abstract][Full Text] [Related]
18. Plasma asymmetric dimethylarginine in infants with bronchopulmonary dysplasia: a promising biomarker despite uncertain pathogenic significance. Aschner JL; Fike CD J Pediatr; 2015 Feb; 166(2):222-4. PubMed ID: 25454308 [No Abstract] [Full Text] [Related]